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oyama and Tokyo, Japan; and Muenster, Germany
OBJECTIVES This study investigated patients with acute Kawasaki disease (KD) to validate myeloid-related
protein (MRP)-8/MRP-14 as a marker of disease activity and severity of coronary artery lesion
development.
BACKGROUND Both MRP-8 and -14, which are S100-proteins secreted by activated neutrophils and monocytes,
bind specifically to endothelial cells and induce thrombogenic and inflammatory responses in a
variety of disease conditions.
METHODS We investigated 61 patients with acute KD and examined sequential changes in serum levels of
MRP-8/MRP-14, messenger ribonucleic acid (mRNA) expression of MRP-8 and -14 in
circulating granulocytes and monocytes, and amounts of MRP-8/MRP-14 bound to circulating
endothelial cells.
RESULTS The serum MRP-8/MRP-14 levels as well as mRNA expressions of MRP-8 and -14 in
granulocytes were strongly upregulated during the early stage of acute KD, and decreased
dramatically within 24 h of intravenous immune globulin therapy (p 0.05) in 45 responders.
In contrast, in 16 nonresponders both of these increased after the initial treatment. The
number of MRP-8/MRP-14–positive circulating endothelial cells was higher in patients with
acute KD than in control patients and increased significantly by 2 weeks after the onset of
KD, especially in patients in whom coronary artery lesions developed.
CONCLUSIONS We show for the first time that MRP-8/MRP-14 are exclusively secreted by granulocytes in
patients with acute KD, and intravenous immune globulin treatment suppresses their gene
expression. Serum levels of MRP-8/MRP-14 may be useful markers of disease activity, and
the levels of MRP-8/MRP-14–positive circulating endothelial cell may predict the severity of
vasculitis, confirming an important role for distinct inflammatory reactions in
endothelium. (J Am Coll Cardiol 2006;48:1257–64) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.077Cardiology Foundation
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lawasaki disease (KD) is the most common systemic vasculitis
yndrome primarily affecting small and medium-sized arteries,
articularly the coronary artery (1). Although timely treatment
ith high-dose intravenous immune globulin (IVIG) is now
ccepted as reducing the incidence of coronary artery lesions
CALs), approximately 15% of the patients do not have a
esponse to IVIG treatment and have a higher incidence of
ALs (2,3). Histopathological studies have shown that the
See page 1265
oronary microvascular lesions are characterized by microvas-
ular dilation, endothelial cell injury, and platelet aggregation
ith thrombosis in the small arterioles during the early stage of
cute KD (4). In addition, transient infiltration by granulocytes
as identified in the very early stage of acute KD, before
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Institute of Experimental Dermatology, Muenster University, Muenster, Germany.
his study was supported by grants from the Japan Kawasaki Disease Research
enter.s
Manuscript received July 26, 2005; revised manuscript received January 23, 2006,
ccepted February 14, 2006.nfiltration of mononuclear cells, suggesting that granulocytes
ct as a trigger in the pathogenesis of CALs (5). A multicenter
andomized controlled study in Japan resulted in guidelines for
he use of IVIG in acute KD, including the criterion of platelet
ounts of 35  104/mm, the so-called Harada score (6).
atients with acute KD with low platelet counts were found to
ave a high incidence of CALs and acute myocardial infarc-
ion, suggesting that a low platelet count is the result of
ntravascular coagulation (7).
Myeloid-related protein (MRP)-8 and -14, 2 S100-proteins,
orm stable heterodimers and are the major calcium-binding
roteins secreted by activated granulocytes and monocytes
8). The protein complex is found in inflammatory fluid in
variety of inflammatory lesions, including rheumatoid
rthritis and inflammatory bowel and lung diseases
9,10). However, little is known of the role of MRP-8/
RP-14 in inflammatory processes. The MRP-8/
RP-14 binds specifically to human microvascular endo-
helial cells via heparan sulfate proteoglycans (11) and via
ovel carboxylated N-glycans (12), suggesting an important
nteraction between MRP-8/MRP-14 and endothelial cells,
lthough the functional consequences and underlying mo-
ecular mechanisms are unresolved. One recent study
howed that MRP-8/MRP-14 induces a thrombogenic and
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Expression of MRP-8 and -14 in Kawasaki Disease September 19, 2006:1257–64nflammatory response in human microvascular endothelial
ells in vitro (13).
We hypothesized that MRP-8/MRP-14 could directly
nduce a distinct inflammatory and thrombogenic response
n the microvascular wall in acute vasculitis syndromes. In
he present study we investigated patients with acute KD
ho were differentiated by responsiveness to IVIG therapy
o validate MRP-8/MRP-14 as a marker of disease activity
nd severity of CAL development. For this purpose, we
xamined sequential changes in serum levels of MRP-8/
RP-14, messenger ribonucleic acid (mRNA) expression
f MRP-8 and -14 in circulating granulocytes and mono-
ytes, and amounts of MRP-8/MRP-14 bound to circulat-
ng endothelial cells.
ETHODS
tudy population and blood samples. Sixty-one patients
ith acute KD (40 male, 21 female), ages 2 months to 7 year
months (median 2.6 years), were enrolled between April
001 and April 2005. Thirty-three age-matched healthy
ontrol patients were enrolled during the same period. We
ave been analyzing these S100-proteins in completely
ifferent cohorts of subjects with ages ranging from 2 to 76
ears (10). We confirmed that there is no evidence showing
hat the levels do vary with age. The patients were seen at
he Toyama University Hospital or at one of five affiliated
ospitals. All patients fulfilled the diagnostic criteria and
ere treated with IVIG (2 g/kg body weight for 1 day) as
ell as oral aspirin (30 mg/kg/day) (14). The responders
ere designated as the patients whose fever subsided within
8 h of IVIG treatment. Nonresponders received a second
reatment of IVIG (2 g/kg body weight for 1 day). Two-
imensional echocardiography was performed before and
fter treatment with IVIG as well as at 2, 3, and 4 weeks
fter the onset of KD, which was defined as the day on
hich fever developed. A coronary artery with a diameter of
mm or more (4 mm if the subject was over the age of 5
ears) by echocardiogram was considered abnormal (14).
he presence of CALs was assessed 1 month after the onset
f KD. Parental informed consent was obtained for each
Abbreviations and Acronyms
CAL  coronary artery lesions
CRP  C-reactive protein
IVIG  intravenous immune globulin
KD  Kawasaki disease
mRNA  messenger ribonucleic acid
MRP  myeloid-related protein
PBS  phosphate-buffered saline
PCR  polymerase chain reaction
PMA  phorbol 12-myristate 13-acetate
RT  reverse transcriptase
TNF  tumor necrosis factor
WBC  white blood cellshild enrolled in this study, which was approved by the Aesearch Ethics Committee of Toyama Medical and
harmaceutical University Hospital. Blood samples were
ollected at the time of diagnosis before the initiation of
VIG treatment (mean  SD, 5.7  1.5 illness days),
hen immediately after the first IVIG infusion and at 2
nd 4 weeks after disease onset. Blood samples were
ollected from healthy control patients on a single occasion.
etermination of serum MRP-8/MRP-14 levels. The
oncentrations of MRP-8/MRP-14 were determined by a
andwich enzyme-linked immunosorbent assay as described
reviously (15). Briefly, rabbit antisera against recombinant
RP-8 and -14 were produced, and their monospecificity
as tested by immunoreactivity against recombinant
RP-8 and -14 by Western blot analysis of lysates of
onocytes and granulocytes, as well as by immunoreactivity
gainst MRP8- and/or MRP-14–transfected fibroblastoid
ell lines. For calibration, different amounts (0.25 to 250
g/ml) of the native complex of human MRP-8 and -14
ere used, which were isolated from human granulocytes.
he assay has a sensitivity of 0.5 ng/ml and a linear range
etween 1 and 30 ng/ml. Data are expressed in ng/ml
RP-8/MRP-14 and represent the mean of duplicates of
ach of 3 dilutions within the linear range.
ell preparation. Granulocytes and mononuclear cells
ere isolated from the heparinized peripheral blood of
atients and control patients by dextran sedimentation and
icoll-Paque density gradient centrifugation as described
reviously (16). Granulocytes were more than 98% pure as
ssessed by May-Gruwald-Giemsa staining. The cells were
esuspended in Roswell Park Memorial Institute (RPMI)
640 medium containing 10% (v/v) charcoal/dextran-
reated fetal bovine serum (HyClone, Logan, Utah), 10
mol/l glutamine, 100 IU/ml penicillin, and 100 g/ml
treptomycin (Life Technologies, Gaithersburg, Maryland)
nd diluted to 1  106 cells/ml.
NA extraction. Total RNA was extracted from the cell
ellets of granulocytes and mononuclear cells from the patients’
eripheral blood using Trizol reagent (Invitrogen Life Tech-
ologies, Carlsbad, California). The purity and quantity of
NA were determined based on ultraviolet absorbance at 260
nd 280 nm on a Beckman spectrophotometer DU530 (Beck-
an Coulter, Fullerton, California).
eal-time reverse-transcriptase (RT)-polymerase chain
eaction (PCR). The primers used for PCR analysis were
s follows: MRP-8 forward, 5=-AATTGCTAGAGA-
CGAGTGTCCTCA-3=, reverse, 5=-TGCCACGCCCA-
CTTTATCA-3=, MRP-14 forward, 5=-TCCACCAAT-
CTCTGTGAAGCTG-3=, reverse, 5=-CCTCCATGA-
GTGTTCTATGACC-3=, glyceraldehyde phosphate de-
ydrogenase forward, 5=-GCACCGTCAAGGCTGAGA-
C-3=, reverse, 5=-ATGGTGGTGAAGACGCCA-
T-3=. For real-time RT-PCR, RNA from every experimen-
al group was analyzed in duplicate. The complementary
eoxyribonucleic acid was synthesized from 0.5 g of total
NA. Real-time RT-PCR reactions were performed on an
BI PRISM 7000 Sequence Detection System (Applied
B
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September 19, 2006:1257–64 Expression of MRP-8 and -14 in Kawasaki Diseaseiosystems, Foster City, California) using the SYBR RT-
CR kit (Takara, Tokyo, Japan). The baseline emission was
alculated by the average fluorescence intensity from cycles
to 15. The threshold for determining the threshold cycle
alue was set at 10 standard deviations (SDs) above the
aseline. The relative gene expression was calculated by
sing the comparative threshold cycle method as described
17). Gene expression was normalized with respect to the
ndogenous housekeeping gene, glyceraldehyde phosphate
ehydrogenase, which was determined not to have signifi-
antly changed in the different experiments.
ouble-labeling immunocytochemistry for circulating
ndothelial cells. Circulating endothelial cells were quan-
itated by immunofluorescence staining of buffy-coat
mears, as described (18). In brief, the resulting buffy-coat
ellet was resuspended in RPMI 1640 and transferred to six
lides such that each slide would contain cells from the
quivalent of 1 ml whole blood. Smears were air-dried
vernight, fixed in 2% paraformaldehyde in phosphate-
uffered saline (PBS) for 20 min, and permeabilized with
.1% Triton X-100 for 5 min. Cellular autofluorescence was
uenched by two 5-min treatments with 1 mg/ml sodium
orohydride (NaBH4) freshly prepared in PBS. After 20
in of blocking in 10% normal goat serum, slides were
ncubated with primary antibodies (mouse antiendothelial
ell monoclonal antibody, P1H12, Chemicon International,
emecula, California, at a dilution of 1:600; monoclonal
urine antibody 27E10 against the MRP-8/MRP-14 at a
ilution of 1:400), which were diluted in blocking solution
or 1 h at room temperature. After washing in PBS, a biotin
onjugated goat antimouse immunoglobulin G (Vector
aboratories, Burlingame, California) at a dilution of 1:200
as applied for 30 min as a second step of the revelation.
or the third step, Alexa Fluor 594 or 488 streptavidin
Molecular Probes, Eugene, Oregon) was added for 30 min.
egative control patients were performed by omitting the
rimary antibodies. Counter staining of nuclei was done
ith DAPI (4=, 6-diamidino-2-phenylindole), and cover-
lips were mounted with SlowFade Light Antifade (Molec-
lar Probes). No relevant cross-reactivity between the re-
pective antibodies was observed. Preparations were
Table 1. Clinical Laboratory Data of Patients
Responders and Nonresponders
Healthy Control
Number of patients 33
Coronary artery lesion
Gender (male) 16 (46%)
Age, yrs (median, range) 4.1 (0.1–12
Minimum platelet  104/mm3
Maximum platelet  104/mm3
Maximum CRP, mg/dl
Maximum WBC,  103/mm3
Granulocytes (%)
Duration of fever, daysData are mean  SD. p Value is derived from comparison of resp
CRP  C-reactive protein; IVIG  intravenous immune globuvaluated by light microscopy (Laborlux S, Leitz, Germany)
t various magnifications (100 to 400).
timulation of granulocytes and mononuclear cells.
ranulocytes at 1 106cells/ml or mononuclear cells at 1
06cells/ml from 5 healthy control patients were incubated
ith tumor necrosis factor (TNF)-alpha (recombinant hu-
an TNF-alpha; R&D Systems, Inc, Minneapolis, Min-
esota) or with phorbol 12-myristate 13-acetate (PMA:
igma Chemical Co., St. Louis, Missouri), respectively, at a
nal concentration of 10 ng/ml, for 15 min, 30 min, 1 h,
h, and 4 h at 37°C. At each time point the supernatant was
ollected for measurement of MRP-8/MRP-14 concentra-
ions by sandwich enzyme-linked immunosorbent assay,
nd RNA was isolated from the cells and MRP-8/MRP-14
xpression analyzed by real-time RT-PCR, as described in
he previous text.
tatistical analysis. Paired t test and analysis of variance
ith repeated measures were used to test for significance of
he same parameter, within the same group, at 4 points,
espectively. If data do not follow normal distribution,
aired t test and analysis of variance with repeated measures
as replaced by their nonparametric versions. When the
ata followed a normal distribution determined by Shapiro-
ilks test, comparisons between two groups were per-
ormed using an unpaired student t test or a Welch test
epending on equal or unequal variance. If the data did not
ollow a normal distribution, then a Mann-Whitney U test
as used.
ESULTS
atient clinical characteristics and laboratory data. Table 1
hows the clinical characteristics of the 61 KD patients
nrolled, comparing responders to IVIG therapy (n  45)
ith nonresponders (n  16). The nonresponders had
ignificantly lower minimum platelets counts, a significantly
igher maximum concentration of C-reactive protein
CRP), a higher incidence of CALs, and a longer duration
f fever as compared with the responders. There were no
ignificant difference between groups with respect to age
nd the maximum number of white blood cells (WBCs).
Acute KD, Comparing IVIG Treatment
nts Responders Nonresponders p Value
45 16
4 (9%) 6 (40%) 0.01
30 (67%) 10 (69%) NS
2.6 (0.4–7.2) 2.8 (0.2–6) NS
32.2  11.3 23.2  8.0 0.01
58.6  17.3 64.0  20.0 NS
9.9  5.2 15.5  7.4 0.05
15.4  4.1 14.6  8.7 NS
66  17 67  16 NS
6.7  1.5 10.3  3.1 0.01With
Patie
.3)onders and nonresponders.
lin; KD  Kawasaki disease; WBC  white blood cells.
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Expression of MRP-8 and -14 in Kawasaki Disease September 19, 2006:1257–64aximal WBC counts were observed before IVIG treat-
ent, and approximately 70% of the WBCs were granulo-
ytes in both groups.
erum MRP-8/MRP-14 levels. The initial serum levels of
RP-8/MRP-14 were elevated in all 61 patients with KD,
xceeding the levels seen in healthy control patients (mean 
D 260 ng/ml). As shown in Table 2 and Figure 1, the
nitial concentration of MRP-8/MRP-14 in the group of
esponders decreased from 3,251 1,981 ng/ml to 1,265
,012 ng/ml within 24 h of IVIG treatment (p  0.01) and
eached normal levels within 4 weeks (Table 2). In contrast,
he serum MRP-8/MRP-14 levels in nonresponders in-
reased after the initial treatment (4,220  2,669 ng/ml to
,900 4,519 ng/ml, p 0.01), but trended to reduce after
he second treatment. Although no differences in MRP-8/
RP-14 concentration were observed between responders
nd nonresponders before treatment, they were significantly
igher in nonresponders than responders after IVIG treat-
Table 2. Serum Concentrations of MRP-8/MR
Acute KD, Comparing IVIG Treatment Respo
Healthy Control Pat
Number of patients 33
MRP-8/MRP-14 (ng/ml)
Initial 220  40
After IVIG
2 weeks after onset
4 weeks after onset
CRP (mg/dl)
Initial
After IVIG
2 weeks after onset
4 weeks after onset
Data are mean  SD. p Value is derived from comparison
MRP  myeloid-related protein; other abbreviations as i
igure 1. Serum levels of myeloid-related protein (MRP)-8/MRP-14 in
ntravenous immune globulin (IVIG) treatment (left panel) with those wh
efore the initiation of IVIG treatment (5.7 1.5 days). Arrows indicate IVIG tr
VIG in each patient group.ent (p  0.01). When patients with and without CALs
ere compared with each other, it was found that the
ormer had higher maximal concentrations of MRP-8/
RP-14 and CRP than the latter (mean difference 1,580
g/ml, p 0.01 for MRP-8/MRP-14; mean difference 10.7
g/dl, p  0.01 for CRP). The CRP levels varied consid-
rably from patient to patient and increased in number after
reatment, but had reached normal values in 32 of 60 (53%)
atients 2 weeks after therapy. In all patients, a decrease in
RP-8/MRP-14 concentration was associated with sub-
iding fever, whereas the CRP level continued to increase
ven after fever subsided in some patients.
RNA expression of MRP-8 and MRP-14 in granulocytes.
n 10 healthy control patients, the relative quantities of
RP-8 and -14 mRNA were 18.6  15.1 and 8.9  2.3,
espectively, in granulocytes. Both were significantly higher
n the granulocytes of acute KD responders before treatment
ith IVIG, decreasing significantly within 24 h of IVIG
4 and C-Reactive Protein in Patients With
s and Nonresponders
Responders Nonresponders p Value
45 16
3,251  1,981 4,220  2,699 NS
1,265  1,012 4,900  4,519 0.01
531  475 1,509  1,252 0.05
242  178 796  475 0.05
8.5  4.1 11.3  5.6 NS
4.9  6.1 13.4  8.4 0.01
0.9  1.1 4.3  4.1 0.01
0.2  0.2 0.5  0.2 0.05
onders and nonresponders.
le 1.
nts with acute Kawasaki disease comparing patients who responded to
not (right panel). Blood samples were collected at the time of diagnosisP-1
nder
ientspatie
o dideatment. *p 0.01 versus healthy control patients. †p 0.01 versus before
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September 19, 2006:1257–64 Expression of MRP-8 and -14 in Kawasaki Diseasereatment (MRP-8: from 74.4  41.3 to 29.1  26.4, p 
.05; MRP-14: from 50.5  43.2 to 11.2  5.4, p  0.05),
eaching normal levels within 1 month (Fig. 2). In contrast,
he expression of both MRP-8 and -14 was similar to
ontrol patients initially in nonresponders, and then in-
reased after the initial treatment and then decreased after
he second IVIG treatment (Fig. 2). There were significant
ifferences between responders and nonresponders in the
xpression of both MRP-8 and -14 2 weeks after initial
VIG treatment (p 0.05). The MRP-8 and -14 mRNA in
ononuclear cells were below detection limit during the
ourse of acute KD (data not shown).
uantitation of circulating endothelial cells. Peripheral
lood samples from healthy control patients contained a
ery small number of circulating endothelial cells, whereas
eripheral blood samples from patients with acute KD had
ignificantly elevated numbers of circulating endothelial
ells at the time of diagnosis (2.5  5.9 cells/ml vs. 1.0 
.7 cells/ml, p  0.05). The number of circulating endo-
helial cells continued to increase (Fig. 3B), even after IVIG
dministration, and peaked at 2 weeks, which is the time
hen CALs usually develop (Fig. 3). Further, there were
ignificantly increased numbers of circulating endothelial cells
n patients with CALs compared with those without CALs at
weeks after onset (94.6  68.5 cells/ml vs. 20.7  20.4
ells/ml, p  0.05). Although endothelial cells were negative
or MRP-8/MRP-14 (Fig. 3A) in healthy control patients
data not shown), most of the endothelial cells were positive
or MRP-8/MRP-14 in patients with acute KD, and the
roportion of endothelial cells that were MRP-8/MRP-14–
ositive cells remained relatively constant (Fig. 3B).
timulation of granulocytes by TNF-alpha. To show
igure 2. Expressions of myeloid-related protein (MRP)-8 (left panel) and -
o intravenous immune globulin (IVIG) (closed circles) and those who did no
VIG treatment in responders.hat MRP-8/MRP-14 is actively secreted by granulocytes, mranulocytes were incubated with TNF-alpha. As shown in
igure 4A, minimal basal secretion of MRP-8/MRP-14
as detected in unstimulated granulocytes, with a time-
ependent increase in MRP-8/MRP-14 secretion after
timulation with TNF-alpha. In contrast, little MRP-8/
RP-14 was secreted by mononuclear cells incubated with
MA (Fig. 4A). The MRP-8– and -14–specific mRNA
ranscription increased in a time-dependent manner, peaking
t 1 h (Fig. 4B). In mononuclear cells, no MRP-8– or -14–
pecific mRNA was detected during the course of PMA
timulation of mononuclear cells (data not shown).
ISCUSSION
his study shows that the number of circulating endothelial
ells increases in patients with acute KD, particularly if
ALs developed, and that most of the P1H12-positive
ndothelial cells were positive for MRP-8/MRP-14. These
ata are in agreement with previous studies that have
eported increased numbers of activated circulating endo-
helial cell in patients with acute KD (18,19). It seems that
he MRP-8/MRP-14 protein complex can bind to endo-
helium via the interaction of MRP14 with heparan sulfate
roteoglycans or by the MRP-8/MRP-14 complex inter-
cting with carboxylated N-glycans, which are exclusively
xpressed by endothelial cells after inflammatory activation
11,12). Here we show that the vast majority of P1H12-
ositive cells show binding of the 2 S100 proteins MRP-8
nd -14, which may point to a novel molecular mechanism
uring the process of tissue damage in the coronary artery
all. It has been shown in vitro that MRP-8/MRP-14
nduce thrombogenic and inflammatory responses in human
ght panel) in granulocytes in acute Kawasaki disease patients who responded
n circles). *p 0.05 versus healthy control patients. †p 0.05 versus before14 (riicrovascular endothelial cells, leading to platelet adhesion
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Expression of MRP-8 and -14 in Kawasaki Disease September 19, 2006:1257–64nd aggregation under shear stress (13). In our study, the
onresponders had significantly lower minimum platelet
ounts, as well as a significantly higher maximum serum
oncentration of MRP-8/MRP-14, suggesting that the low
latelet counts are a result of severe vasculitis and intravas-
ular coagulation (7).
The IVIG treatment is clearly effective in the rapid
esolution of KD inflammation and in reducing the inci-
ence of CALs. However, the mechanisms of IVIG action
emain unknown. In the acute stage of KD, the serum levels
f inflammatory cytokines are elevated, and decrease after
uccessful IVIG treatment (20). A recent study (21) re-
orted that various gene expressions change in patients with
cute KD in peripheral mononuclear cells after IVIG
reatment, and suggested that IVIG therapy downregulated
arious functional genes. It may reflect that the effect of
VIG was mediated by suppression of an array of immune
ctivation genes in monocytes. Here we show for the first time
hat the expression of MRP-8 and -14 in granulocytes is
ncreased in patients with acute KD, and rapidly decreased
fter successful IVIG treatment in responders. In contrast, in
onresponders the expression of MRP-8 and -14 in granulo-
ytes increased after the initial IVIG treatment and only
igure 3. Immunocytochemical analysis of circulating cells. (A) Buffy-coat
magnification 1,000) (left). A circulating endothelial cell stained for
1,000) (center) in acute Kawasaki disease (KD) patients with coronary a
B) Quantitation of circulating endothelial cells (left) and cells positive for M
.05 patients without CAL versus patients with CAL. Black columns  pecreased after the second IVIG treatment. It had previously Meen reported that MRP-8 and -14 form stable heterodimers
nd are secreted by activated granulocytes and monocytes
8,22). However, in patients with acute KD, mRNA ex-
ression of MRP-8 and -14 were below the detection limit
n peripheral blood mononuclear cells in our present study.
hese data suggest that granulocytes have an important role
n triggering the vasculitis in acute KD. Interestingly, a
eutrophil-elastase inhibitor, ulinastatin, has been reported to
e an alternative therapeutic approach for KD, especially in
onresponders to IVIG treatment (23).
The present study confirms that MRP-8 and -14 are
otential markers for monitoring KD and are more reliable
han CRP in determining the response to IVIG treatment
ecause serum levels correlated with disease activity in
ndividual patients. Further, nonresponders to IVIG treat-
ent had higher initial and maximum MRP-8/MRP-14
nd CRP levels than responders, suggesting that MRP-8
nd -14 may not only serve as diagnostic markers, but also
hat they are involved in the pathophysiology of systemic
asculitis in acute KD. Although the function of MRP-8/
RP-14 has not been fully elucidated, there is evidence
hat it plays a pivotal role during inflammatory conditions.
upporting this idea, we showed that TNF-alpha promotes
-stained with P1H12 showing a circulating endothelial cell (red staining)
oid-related protein (MRP)-8/MRP-14 (green staining) (magnification
lesions (CAL). Nuclei stained with DAPI (magnification 1,000 (right).
-8/MRP-14 (right) in patients with acute KD with or without CAL. *p 
ts with CAL (n  9); white columns  patients without CAL (n  15).smear
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September 19, 2006:1257–64 Expression of MRP-8 and -14 in Kawasaki Diseasend increases the secretion of MRP-8/MRP-14 from granu-
ocytes in vitro. Thus, we hypothesize that serum MRP-8/
RP-14 levels and MRP-8 and -14 expression in granulo-
ytes may serve as markers confirming responsiveness to
VIG treatment. Elevated MRP-8/MRP-14 serum levels in
ctive disease, sustained MRP-8/MRP-14 mRNA expres-
ion in nonresponders, and increased numbers of circulating
RP-8/MRP-14–positive endothelial cells in patients with
ALs point to a role of these proteins during the patho-
enesis of KD.
tudy limitations. We were unable to perform immuno-
istochemical analyses of myocardium and coronary arteries
ecause autopsy cases of acute KD were not available. A
revious study showed that the endothelium of the vessels
re almost completely coated with MRP-8 and -14, and
howed a massive adhesion of MRP-8/MRP-14–positive
ranulocytes to the endothelium (13). In the study of
RP-8/MRP-14 transcription, samples from just three
onresponders were studied; they had similar expression
rofiles, however.
onclusions. Our results suggest that serum MRP-8/
RP-14 levels closely correlate with disease activity in
cute KD, and that IVIG treatment suppresses the expres-
ion of the MRP-8 and -14 genes in granulocytes. More-
ver, the fact that MRP-8/MRP-14–positive endothelial
ells are significantly different already at 2 weeks after onset
igure 4. (A) Myeloid-related protein (MRP)-8/MRP-14 levels in th
TNF)-alpha (left) or mononuclear cells with phorbol 12-myristate 13-ac
RNA in granulocytes after stimulation with TNF-alpha. *p  0.01 versn KD could well serve as a meaningful marker identifyingatients at risk for developing CALs. Our data imply an
mportant functional role for MRP-8/MRP-14 and suggest
hat novel, directed inhibitory agents may be useful in
reating human vasculitis syndromes.
cknowledgments
he authors are grateful to Dr. Atsuko Suzuki, and to Dr.
ideki Origasa for his assistance in analyzing the data. The
uthors thank Harue Tsuji, Hiroki Matsukura, Ayumi
iyazaki, Ken Suzaki, Masayoshi Miura, Gyokei Murakami,
iromichi Kubota, Kyoko Nakaaki, Youichi Onoue, Ken-
aro Shinozaki, Hiromichi Taneichi, Tatsuya Fuchizawa,
otokazu Nakabayashi, Osamu Higuchi, Yasunori Itou,
akashi Kuramoto, Hisano Sakaki, Keiji Ibuki, and Ka-
uyoshi Saito for their invaluable contributions to collection
f patient samples. The authors also thank Yukie Ono,
hikako Sakai, Hitoshi Moriuchi, and Neil E. Bowles for
heir excellent assistance.
eprint requests and correspondence: Dr. Fukiko Ichida, Depart-
ent of Pediatrics, Toyama University, 2630 Sugitani, Toyama,
30-0194 Japan. E-mail: fukiko@ms.toyama-mpu.ac.jp.
EFERENCES
ernatant after stimulation of granulocytes with tumor necrosis factor
(right). (B) Relative quantification of MRP-8 (left) and MRP-14 (right)
fore stimulation. †p  0.05 versus before stimulation.e sup1. Kato H, Sugiyama T, Akagi T, et al. Long-term consequences of
Kawasaki disease. Circulation 1996;94:1379–85.
11
1
1
1
1
1
1
1
1
2
2
2
2
1264 Hirono et al. JACC Vol. 48, No. 6, 2006
Expression of MRP-8 and -14 in Kawasaki Disease September 19, 2006:1257–642. Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of
Kawasaki disease in children. Circulation 1993;87:1776–80.
3. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for
immune globulin-resistant Kawasaki disease: a comparative study of
additional immune globulin and steroid pulse therapy. Pediatr Int
2001;43:211–7.
4. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki
disease. Pediatrics 1978;61:100–4.
5. Naoe S, Shibuya K, Takahashi K, et al. Pathological observations
concerning the cardiovascular lesions in Kawasaki disease. Cardiol
Young 1991;1:212–20.
6. Harada K. Intravenous gamma-globulin treatment in Kawasaki dis-
ease. Acta Paediatr Jpn 1991;33:805–10.
7. Niwa K, Aotsuka H, Hamada H, et al. Low platelet counts: a risk
factor for acute myocardial infarction during the acute phase of
Kawasaki disease. Coron Artery Dis 1995;6:857–64.
8. Roth J, Vogl T, Sorg C, Sunderkötter C. Phagocyte-specific S100
proteins: a novel group of proinflammatory molecules. Trends Immu-
nol 2003;24:155–8.
9. Frosch M, Vogl T, Seeliger S, et al. Expression of myeloid-related
protein 8 and 14 in systemic-onset juvenile rheumatoid arthritis.
Arthritis Rheum 2003;48:2622–6.
0. Foell D, Roth J. Proinflammatory S100-proteins in arthritis and
autoimmune disease. Arthritis Rheum 2004;50:3762–71.
1. Robinson MJ, Tessier P, Poulsom R, Hogg N. The S100 family
heterodimer, MRP-8/14, binds with high affinity to heparin and
heparin sulfate glycosaminoglycans on endothelial cells. J Biol Chem
2002;277:3658–65.
2. Srikrishna G, Panneerselvam K, Westphal V, et al. Two proteins
modulating transendothelial migration of leukocytes recognize novel
carboxylated glycans on endothelial cells. J Immunol 2001;166:4678–88.
3. Viemann D, Strey A, Janning A, et al. Myeloid-related protein 8 and
14 induce a specific inflammatory response in human microvascular
endothelial cells. Blood 2005;105:2955–62.4. Shulman ST, Inocencio J, Hirsch R. Kawasaki disease. Pediatr Clin
North Am 1995;42:1205–22.
5. Roth J, Burwinkel F, van den Bos C, et al. MRP-8 and -14, S-100-like
proteins associated with myeloid differentiation, are translocated to
plasma membrane and intermediate filaments in a calcium-dependent
manner. Blood 1993;15:1875–83.
6. Futatani T, Miyawaki T, Tsukada S, et al. Deficient expression of
Bruton tyrosine kinase in monocytes from X-linked agammaglobu-
linemia as evaluated by a flow cytometric analysis and its clinical
application to carrier detection. Blood 1998;91:595–602.
7. Liu W, Saint DA. A new quantitative method of real time reverse
transcription polymerase chain reaction assay based on simulation of
polymerase chain reaction kinetics. Anal Biochem 2002;302:52–9.
8. Yu X, Hirono KI, Ichida F, et al. Enhanced iNOS expression in
leukocytes and circulating endothelial cells is associated with the
progression of coronary artery lesions in acute Kawasaki disease.
Pediatr Res 2004;55:688–94.
9. Nakatani K, Takeshima S, Tsujimoto H, et al. Circulating endothelial
cells in Kawasaki disease. Clin Exp Immunol 2003;131:536–40.
0. Terai M, Jibiki T, Harada A, et al. Dramatic decrease of circulating
levels of monocyte chemoattractant protein-1 in Kawasaki disease after
gamma globulin treatment. J Leukoc Biol 1999;65:566–72.
1. Jun A, Toshiaki J, Seiji N, et al. Gene expression profiling of the effect
of high-dose intravenous Ig in patients with Kawasaki disease. J Im-
munol 2005;174:5837–45.
2. Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein
(MRP) 8 and MRP14, calcium-binding proteins of the S100 family,
are secreted by activated monocytes via a novel, tubulin-dependent
pathway. J Biol Chem 1997;272:9496–502.
3. Zaitsu M, Hamasaki Y, Tashiro K, et al. Ulinastatin, an elastase
inhibitor, inhibits the increased mRNA expression of prostaglandin
H2 synthase-type 2 in Kawasaki disease. J Infect Dis
2000;181:1101–9.
